Currently, two ongoing clinical trials are investigating the role of GLP-1 RAs in IBD management, that would lead to further knowledge: a French study (ID NCT05196958) evaluating the safety and efficacy of GLP-1 RAs in treatment of DM2 in overweight IBD patients (115), and an American study (ID NCT06774079) comparing the efficacy of GLP-1 RAs tirzepatide versus diet in CD patients (116). This evidence concerns the gene GCG and inflammatory bowel disease.